Published on 10 May 2024 on Zacks via Yahoo Finance
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Xenon Pharmaceuticals Inc. XENE reported a loss of 62 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 69 cents. The company had incurred a loss of 63 cents per share in the year-ago quarter.
In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.